Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062647 · ClinicalTrials.gov registry record · Phase 2
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00062647: Completed Phase 2 study, sponsored by Cumberland Pharmaceuticals.
NCT00062647 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062647, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
Primary Outcome
Outcomes in this exploratory study were compared for noninferiority though no specific margin was justified. The 95% CI for the difference was -35.5 to 31.9; further statistical evaluation is not warranted owing to the small sample size.
Interventions
- DRUG Telavancin
- DRUG Vancomycin, nafcillin, oxacillin, or cloxacillin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00062647 record still lists
NCT00062647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Telavancin is the first listed.
NCT00062647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00062647 about?
NCT00062647 is a clinical study titled "Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia". The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
What is the current status of trial NCT00062647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2003-08. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00062647?
The interventions under investigation include: Telavancin (DRUG), Vancomycin, nafcillin, oxacillin, or cloxacillin (DRUG).
Who is sponsoring clinical trial NCT00062647?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00062647's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia